Granules India Limited · NSE:GRANULES
Granules India — Q1 FY2023 Earnings Presentation
15 slides from Granules India's earnings presentation, Aug 9, 2022
Slide 1: Cover letter to NSE/BSE: Presentation to Analysts/Investors
G GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, India. Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com CIN: L24110TG1991PLC012471 Dated August 09, 2022 To, National Stock Exchange
Slide 2: Granules India Limited Q1FY23 Earnings Presentation
Granules India Limited Q1FY23 Earnings Presentation 1
Slide 3: Safe Harbor
Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 4: Q1FY23 Financial Highlights
Q1FY23 Financial Highlights Income from Operations (Rs. Mn.) Gross margin and margin% (Rs. Mn.) EBITDA and EBITDA margins (Rs. Mn.) 5,060 5,039 10,300 10,196 9,968 2,115 2,014 8,883 1,927 8,498 1,737 1,512 4,648 4,607 4,517 23.7% 20.7% 46.6% 48.9% 49.6% 17.0% 17.4% 18.7% 54.2% 50.9% 17.4% 25.1% Q1FY
Slide 5: Geographical Mix
Q1FY23 Revenue spilt by Market, Molecules and Segments (In ₹ Mn) Growth in Europe due to higher Paracetamol sales Finished Dosage and PFI segments grew 21% and 38% Q1FY22 Q1FY23 10,196 5.4% 6.5% 8.1% 8,498 Geographical Mix 13.8% Segment Revenue 50.3% 9.2% 5,487 49.6% FD 10.9% 4,545 PFI API 22.5% 1,7
Slide 6: Financial and Business Summary for Q1FY23
Financial and Business Summary for Q1FY23 ▪ Revenue for Q1FY23 stood at INR 10,196 Mn, growth of 20% YoY across all geographies and segments. Revenue share from Europe increased to 22.5% when compared to 16.8% YoY. ▪ Revenue share of non-core molecules stood at 18% Q1FY23 when compared to 17% Q1FY22
Slide 7: Q1 FY23 Financial Ratios
Q1 FY23 Financial Ratios (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Operational Cash Flow Free Cash Flow 1,807 1.03 1.00 981 1,328 0.93 324 1,005 49 7,232 0.78 754 6,966 0.72 6,576 6,298 6,132 (303) 233 (718) Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22 Q3FY22
Slide 8: ANDA/Dossier filing status
ANDA/Dossier filing status GPI IP GIL IP Filing Status Total USA USA Europe Canada South Africa UK Approved 24 24 4 3 1 56 Tentatively Approved 1 1 2 To be approved 5 11 3 2 2 1 24 Total Products 30 36 7 5 2 2 82 Total GPI products include: ANDA/Dossier filed - Therapeutic area wise CII – 7 Analgesi
Slide 9: Revenue trend – percentage share from Core and Other Molecules
Revenue trend – percentage share from Core and Other Molecules Core Others Para MF IBU GGF MCB Others 14% 17% 15% 16% 14% 15% 16% 14% 14% 15% 19% 17% 18% 19% 17% 16% 3% 16% 1%34% 26% 3% 3% 5% 5% 3% 6% 3% 3% 4% 3% 17% 18% 13% 19% 25% 6% 19% 29% 25% 17% 33% 26% 86% 85% 84% 21% 21% 86% 83% 86% 85% 81%
Slide 10: 5-year trajectory: Key Ratios and Cash Flow
5-year trajectory: Key Ratios and Cash Flow (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Cash-to-Cash cycle (days) Free Cash Flow (FCF) 9,082 2,919 8,704 135 138 125 3.1 114 117 1,615 6,966 109 6,138 6,058 5,752 2.4 2.1 (172) (647) (1,284) 1.2 1.0 0.7 (4,471) Mar-17 Mar-18 Mar-19 Mar-20 Mar-21 Mar-22
Slide 11: 5-year trajectory: Revenue and Profitability
5-year trajectory : Revenue and Profitability (In ₹ Mn) Revenue Gross Profit & Gross Margin 37,649 18,463 18,813 32,375 25,986 13,177 22,792 10,236 57.0% 16,918 7,955 14,353 7,556 50.7% 52.6% 52.6% 47.0% 44.9% 57.0% 47.0% 44.9% 50.7% 49.97% FY 17 FY 18 FY17 FY 19 FY18 FY 20 FY19 FY 21 FY20 FYFY21 22
Slide 12: 5-year trajectory: Market and Segment mix
5-year trajectory: Market and Segment mix (In ₹ Mn) Higher revenue contribution coming from Finished Dosage contribution in value going FD segment share increased to 40% to 52% regulated market, 73% of total revenues up in last 5yrs 5% 5% 4% 6% 5% 15% 14% 12% 20% 20% 19,442 39.9% 8% 10% 47.1% 9% 52.
Slide 13: Granules 2.0
Granules 2.0 Strengthening the Drive cost leadership and EBITDA transformation, through strong focus on cost Core management Commercial excellence incl. new product launch management capabilities to propel growth in US and other geographies. B2B business with focus on value-add APIs. Build the formu
Slide 14: Glossary
Glossary API: Active Pharmaceutical Ingredient PFI: Pharmaceuticals Formulation Intermediates FD: Finished Dosage OTC: Over the counter drugs Rx: Prescription drugs IR: Immediate Release ER: Extended Release CII: Control substances PFOS: Powder for oral suspensions and solutions MUPS: Multi-unit pel
Slide 15: Corporate address
Mr. Krishna Raghunathan VP Finance and Investor Relations Email: krishna.raghunathan@granulesindia.com www.granulesindia.com Ms. Payal Dave payal.dave@linkintime.co.in Mr. Ashish Chovatia +91 9930044680 ashish.chovatia@linkintime.co.in www.orientcap.com 532482 GRANULES Corporate address: GRAN:IN Flo